Telix PharmaceuticalsTLX
13F holders, Q1 2025 (March 31)6holders +5
5new positions
0sold out
$16.76avg. 13F price*
At the end of Q1 2025, 6 institutions reported holding Telix Pharmaceuticals Ltd. (TLX) in their 13F filings, up 5 from Q4 2024. 5 opened new positions and 0 sold out. The largest holders were Abc Arbitrage SA ($451K), Private Advisor Group, LLC ($170K) and Morgan Stanley ($94K).
- Company
- Telix Pharmaceuticals Ltd.
- CUSIP
- 87961M105
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 5 | $737K |
| Exits | 0 | $0 |
All 13F filers, Q4 2024 → Q1 2025: 43,996 shares bought and 79 shares sold, net +43,917 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 6 holders
| Abc Arbitrage SA | 0.08% | New | 26,939 | $451K |
| Private Advisor Group, LLC | 0.00% | New | 10,140 | $170K |
| Morgan Stanley | 0.00% | New | 5,634 | $94K |
| UBS Group AG | 0.00% | Reduce -2.1% | 3,651 | $61K |
| Rhumbline Advisers | 0.00% | New | 1,146 | $19K |
| EverSource Wealth Advisors, LLC | 0.00% | New | 137 | $2K |
"% of holder's portfolio" is TLX's weight in each manager's 13F, not the share of Telix Pharmaceuticals Ltd. the manager owns.